KLK1, Kallikrein-1, KLKR, Klk6, hK1
Recombinant Human KLK1 /Kallikrein-1 Protein (rhKallikrein-1 /KLK1) Pro 19 - Ser 262 (Accession # NP_002248) was produced in human 293 cells (HEK293) at ACRObiosystems.
rhKallikrein-1 /KLK1, fused with polyhistidine tag at the C-terminus, has a calculated MW of 27.9 kDa. The predicted N-terminus is Pro 19. DTT-reduced Protein migrates as 40-45 kDa due to glycosylation.
Less than 1.0 EU per μg of the rhKallikrein-1 /KLK1 by the LAL method.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 2 mM CaCl2, 150 mM NaCl, pH 7.5. Normally Mannitol or Trehalose are added as protectants before lyophilization.
Contact us for customized product format or formulation.
See Certificate of Analysis for details of reconstitution instruction and specific concentration.
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4oC); After reconstitution under sterile conditions for 3 months (-70oC).
Kallikrein-1 (KLK1) belongs to the peptidase S1 family and Kallikrein subfamily. KLK1 contains one peptidase S1 domain. KLK-1 preferential cleavage of Arg-|-Xaa bonds in small molecule substrates and also has highly selective action to release kallidin (lysyl-bradykinin) from kininogen involves hydrolysis of Met-|-Xaa or Leu-|-Xaa. Glandular kallikreins cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.